Learn More
Selleck Chemical LLC Ralimetinib dimesylate 5mg 862507-23-1 LY2228820 dimesylate

Supplier: Selleck Chemical LLC S14945MG
Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2. *For Research & Development use only. Product is not intended for drug, household, or human consumption.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.